GoodRx Holdings, Inc. (NASDAQ:GDRX) – Equities research analysts at SVB Leerink increased their Q4 2020 EPS estimates for GoodRx in a research note issued to investors on Tuesday, November 17th. SVB Leerink analyst S. Demko now forecasts that the company will post earnings per share of ($0.44) for the quarter, up from their previous forecast of ($0.45). SVB Leerink has a “Outperform” rating and a $61.00 price objective on the stock. SVB Leerink also issued estimates for GoodRx’s FY2021 earnings at $0.11 EPS and FY2022 earnings at $0.34 EPS.

GDRX has been the topic of a number of other research reports. Raymond James assumed coverage on GoodRx in a research note on Monday, October 19th. They issued a “market perform” rating and a $61.00 price objective on the stock. Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and set a $56.00 target price on the stock in a research report on Thursday. The Goldman Sachs Group assumed coverage on GoodRx in a research report on Monday, October 19th. They set a “neutral” rating and a $48.00 target price on the stock. Morgan Stanley lowered GoodRx from an “overweight” rating to an “equal weight” rating and set a $36.00 target price on the stock. in a research report on Wednesday. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell assumed coverage on GoodRx in a research report on Monday, October 19th. They set a “buy” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $50.85.

GDRX opened at $38.80 on Friday. GoodRx has a one year low of $33.51 and a one year high of $64.22. The stock has a fifty day moving average price of $49.89.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.12. The business had revenue of $140.40 million for the quarter, compared to the consensus estimate of $135.05 million. The firm’s quarterly revenue was up 37.9% on a year-over-year basis.

Several hedge funds have recently modified their holdings of the company. Stuart Chaussee & Associates Inc. purchased a new position in shares of GoodRx during the third quarter valued at $49,000. Crewe Advisors LLC purchased a new position in shares of GoodRx during the third quarter valued at $83,000. Evolution Wealth Advisors LLC purchased a new position in shares of GoodRx during the third quarter valued at $111,000. Emerald Advisers LLC purchased a new position in shares of GoodRx during the third quarter valued at $125,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of GoodRx during the third quarter valued at $210,000.

About GoodRx

GoodRx Holdings, Inc is a holding company. The company, through its subsidiaries, owns and operates a prescription drug price comparison platform using data from local and mail-order pharmacies in the United States. It also provides pharmacy coupons to customers. The company offers generic and brand name pricing; alerts clients on manufacturer co-pay cards, pharmacy discounts, and state discount programs; and provides tips on slashing drug prices.

See Also: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.